ArticleAmerican journal of translational research2022
Neuroprotective mechanism of crocin via PI3K/Akt/mTOR signaling pathway after cerebral infarction: an
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Review
- Crocin alleviates neuronal arborization damage in the basolateral nucleus of the amygdala and dentate gyrus of the hippocampus in a stressed rat.IBRO neuroscience reports · 2025Article
- Is Crocin Effective in Modulating Blood Lipid Levels? An Updated Systematic Review and Meta-Analysis with Dose- and Time-Response Assessments.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Crocin ameliorates neuroinflammation and cognitive impairment in mice with Alzheimer's disease by activating PI3K/AKT pathway.Brain and behavior · 2024Article
- Review
- Tibetan Medicine Shi-Wei-Gan-Ning-San Alleviates Carbon Tetrachloride-Induced Chronic Liver Injury by Inhibiting TGF-Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the potential neuroprotective mechanism of crocin after cerebral infarction.
methodsThe murine hippocampal neuronal cell line HT-22, was used as the study model, with a control group, OGD-group, low-dose crocin group, middle-dose crocin group, and high-dose crocin group. Except for the control-group, cells in the other groups were treated with OGD for 6 h, in which 1 μg/mL, 2 μg/mL and 5 μg/mL of crocin were added in low-dose group, medium-dose group and high-dose group, respectively. Subsequently, the OGD cells were cultured for another 6 h. CCK-8 assay was carried out to detect the cell viability of each group, flow cytometry was used to detect cell apoptosis, immunofluorescence was conducted to detect the expression of reactive oxygen species, and Western Blot was performed to detect the protein expression of p-PI3K, p-Akt, p-mTOR, LC-3 I, LC-3 II, and Beclin-1.
resultsAfter hypoxia-reoxygenation treatment, the viability of HT22 cells was remarkably decreased, the apoptosis rate and expression of ROS were significantly increased, the protein expression of p-PI3K, p-Akt and p-mTOR were reduced, while the expression of LC-3 II/I and Beclin-1 were increased. After crocin treatment, the activity of hypoxic reoxygenated cells increased, the apoptosis rate decreased, the expression of reactive oxygen species dropped, the protein expression of p-PI3K, p-Akt and p-mTOR increased, and the expression of LC-3 II/I and Beclin-1 decreased.
conclusionAt the cellular level, crocin can inhibit autophagy by activating the PI3K/Akt/mTOR pathway, and reduce the level of oxidative stress, thus playing a neuroprotective role.
Indexed as
Identifiers
35702067PMC9185057W4285740708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.